Format

Send to

Choose Destination
J Affect Disord. 2015 Aug 1;181:87-91. doi: 10.1016/j.jad.2015.04.012. Epub 2015 Apr 15.

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder.

Author information

1
Stanford University, Stanford, CA, USA. Electronic address: tketter@stanford.edu.
2
Teva Pharmaceutical Industries Ltd., Frazer, PA, USA.
3
Mayo Clinic, Rochester, MN, USA.

Abstract

BACKGROUND:

In a previous study, adjunctive armodafinil 150 mg/day significantly improved depressive symptoms associated with bipolar I disorder.

METHODS:

Multicenter, double-blind study of patients with a major depressive episode despite bipolar I disorder maintenance therapy randomized to adjunctive placebo or adjunctive armodafinil 150 or 200mg/day for 8 weeks; for logistical reasons, assignment to armodafinil 200mg/day was discontinued early. Primary efficacy was measured by change from baseline to week 8 in 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) total score.

RESULTS:

Patients were randomized to adjunctive placebo (n=230), adjunctive armodafinil 150 mg/day (n=232), or adjunctive armodafinil 200mg/day (n=30; analyzed for safety only). Least-square mean change in IDS-C30 total score was numerically superior for adjunctive armodafinil 150 mg/day vs adjunctive placebo, but was not statistically significant (p=0.13). Armodafinil was well-tolerated. Adverse events (AEs) observed in >5% with adjunctive armodafinil 150 mg/day and more frequently than with adjunctive placebo were headache (16% [38/231] vs 13% [30/229]) and nausea (7% [17/231] vs 2% [5/229]). The most common AEs with adjunctive armodafinil 200mg/day were diarrhea and dry mouth (17% [5/30] each vs 6% [13/229] and 1% [3/229], respectively, with adjunctive placebo).

LIMITATIONS:

Early study discontinuation for logistical reasons by the sponsor limited adjunctive armodafinil 200-mg/day assessment.

CONCLUSIONS:

FDA-approved bipolar I depression treatments are limited. Adjunctive armodafinil 150 mg/day reduced depressive symptoms associated with bipolar I disorder to a greater extent than adjunctive placebo, although the difference failed to reach statistical significance. Safety data indicate treatment with adjunctive armodafinil was well-tolerated.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01072630.

KEYWORDS:

Armodafinil; Bipolar I disorder; Major depressive episodes

PMID:
25933099
DOI:
10.1016/j.jad.2015.04.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center